Skip to content

A Study of the Effect of a Nurse Navigator Program on High Risk Patients

The Effect of a Nurse Navigator Program on Readmission Rates for Patients With Elevated BMI, COPD, CHF, Dialysis Use, and H/o Alcohol Abuse

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05592847
Enrollment
300
Registered
2022-10-25
Start date
2027-01-01
Completion date
2027-06-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Body Mass Index, Heart Failure, Patient Readmission, Pulmonary Disease, Chronic Obstructive, Renal Insufficiency

Brief summary

The purpose of this study is to examine if educational intervention in high risk patients can lead to decreased hospital readmissions when compared to patients who are not in the intervention program. Additionally, to determine patient satisfaction with the educational program.

Interventions

OTHERNurse Navigator Program

Identification of specific chronic conditions and suggestion of management care of primary care physicians and referrals to specialists via nurse navigator team members.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Require total or partial hip or knee replacement and have one or more of the following diagnosis: Heart Failure (HF); Chronic obstructive pulmonary disease (COPD); Dialysis; Alcohol Abuse; Low BMI.

Exclusion criteria

\- Decrease cognitive capacity to consent to the study.

Design outcomes

Primary

MeasureTime frame
Readmission ratesOne year

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGeorge Pujalte, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026